Alzamend Neuro Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	7.42	7.12	3.64	3.35	1.31
Research & Development	7.45	5.2	1.31	1.07	3.7
Operating Expenses	14.87	12.32	4.95	4.42	5.01
Operating Income	-14.87	-12.32	-4.95	-4.42	-5.01
Interest Expense / Income	0.01	0.05	0.16	0	0
Other Expense / Income	-	-0	-0.06	-0.01	-0.15
Pretax Income	-14.88	-12.36	-5.05	-4.41	-4.86
Net Income	-14.88	-12.36	-5.05	-4.41	-4.86
Shares Outstanding (Basic)	7	6	5	5	4
Shares Outstanding (Diluted)	7	6	5	5	4
Shares Change	9.45%	22.64%	1.96%	21.09%	-
EPS (Basic)	-2.25	-2.10	-1.05	-0.90	-1.20
EPS (Diluted)	-2.25	-2.10	-1.05	-0.90	-1.20
Free Cash Flow	-8.92	-6.72	-2.71	-2.35	-1.05
Free Cash Flow Per Share	-1.37	-1.13	-0.56	-0.49	-0.27
EBITDA	-14.85	-12.31	-4.89	-4.41	-4.86
Depreciation & Amortization	0.02	0	0	0	0
EBIT	-14.87	-12.32	-4.89	-4.41	-4.86

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).